The hyperhomocysteinemia is associated with the development and the accentuation of the cardiovascular complications of the type 2 diabetes. The objective of this study was to evaluate the hyperhomocysteinemia in type 2 diabetic patients. This study was carried out in 200 volunteer type 2 diabetics, regularly monitored at the Antidiabetic Center of Abidjan (CADA). The non-diabetic control population was composed of 31 healthy presumptive volunteers. The homocysteine, the glycemia and the lipid parameters were measured by enzymatic methods on the biochemistry automaton Cobas c-311(Roche Diagnostics). The present study has revealed a prevalence of a moderate hyperhomocysteinemia of 36.50%. The average hyperhomocysteinemia was of 14.84 ± 3.26 μmol/L. It was higher in men (14.95 ± 3.50μmol/L) than in women (14.75 ± 3.05μmol/L), with no significant difference, and was predominant in the Akan ethnic group (57.53%). It evolved with age and was significantly increased between 50 and 70 years. The relative risk of the hyperhomocysteinemia was approximately 3 (RR = 2.83≈3, CI 95%: 1.39-11.53, P(χ2 )
